Premium
Soluble fas ligand in natural killer cell lymphoma
Author(s) -
Murayama Tohru,
Koizumi Tamio,
Das Hiranmoy,
Kobayashi Yukio,
Kajimoto Kazuyoshi,
Sugimoto Takeshi,
Imoto Shion,
Nishimura Ryuichiro,
Nakagawa Toshitaro
Publication year - 1999
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199912)62:4<253::aid-ajh11>3.0.co;2-h
Subject(s) - fas ligand , lymphoma , immunology , effector , medicine , liver function , cancer research , biology , apoptosis , programmed cell death , biochemistry
We measured serum soluble Fas ligand (sFasL) in a patient with natural killer cell lymphoma, and investigated relationship between sFasL and liver dysfunction. An elevated level of sFasL was decreased after local radiation therapy, and liver function improved. When lymphoma relapsed, liver dysfunction reappeared and the level of sFasL increased parallelly. Lymphoma cells expressed mRNA of FasL. This suggested that this liver dysfunction was induced by some remote effectors, and sFasL was one of candidates of these effectors. Am. J. Hematol. 62:253–255, 1999. © 1999 Wiley‐Liss, Inc.